• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Aiforia: We diagnose a growth deficiency

Research 23.07.2026, 09.25 by Antti Siltanen
Aiforia Technologies

Aiforia's H1 revenue was surprisingly subdued

Analyst Comment 22.07.2026, 08.05 by Antti Siltanen
Aiforia Technologies

Orion Q2'26: Engangsmedvind bidrog til topresultatet

Research 20.07.2026, 07.00 by Antti Siltanen
Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Orion Q2'26 preview: Royalties øger resultatet

Analyst Comment 13.07.2026, 06.20 by Antti Siltanen
Orion

Orion indgår aftale om rettigheder til vigtigt biosimilært lægemiddel i Europa

Analyst Comment 30.06.2026, 07.55 by Antti Siltanen
Orion

Biohit: Sold on summer sale

Research 29.06.2026, 08.00 by Antti Siltanen
Biohit

Herantis appointed a Chief Medical Officer

Analyst Comment 26.06.2026, 07.51 by Antti Siltanen
Herantis Pharma

Aiforia collects 6.4 MEUR in a directed share issue

Analyst Comment 26.06.2026, 07.49 by Antti Siltanen
Aiforia Technologies

Bioretec Extensive Report: Signs of recovery in growth fracture

Extensive research 25.06.2026, 13.13 by Antti Siltanen
Bioretec

Orions ODM-212 fik også særstatus som lægemiddel i EU

Analyst Comment 24.06.2026, 06.00 by Antti Siltanen
Orion